Vermillion said last week that it has rehired its former chief scientific officer.
Eric Fung will rejoin the company upon the completion of its restructuring and reorganization under Chapter 11 bankruptcy, or earlier if Vermillion's board deems it appropriate.
In the interim, Fung will be an independent consultant to the firm.
Fung had been Vermillion's CSO from 2006 until this past March, shortly before it filed for Chapter 11 protection.
In a statement, Gail Page, executive director of Vermillion, said that Fung "was instrumental in the development" of its OVA1 test for ovarian cancer, which was approved by the US Food and Drug Administration last month. "We are pleased to welcome him back to Vermillion, where he will play a key role in commercialization of the OVA1 test as well as further development of other potential tests in Vermillion's pipeline,” Page added.
Fung joined Vermillion in 2000, when the company was called Ciphergen, as a lead scientist in the company's Biomarker Discovery Center. Before that, he was director of clinical research at Roche Molecular Systems.
He was also a Howard Hughes-sponsored researcher at Stanford University, and obtained his MD and PhD from the Johns Hopkins University School of Medicine.